Moderna Inc (MRNA)
104.46
+3.05
(+3.01%)
USD |
NASDAQ |
Apr 22, 16:00
104.93
+0.47
(+0.45%)
After-Hours: 05:47
Moderna Research and Development Expense (Quarterly): 1.406B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.406B |
| September 30, 2023 | 1.16B |
| June 30, 2023 | 1.148B |
| March 31, 2023 | 1.131B |
| December 31, 2022 | 1.211B |
| September 30, 2022 | 820.00M |
| June 30, 2022 | 710.00M |
| March 31, 2022 | 554.00M |
| December 31, 2021 | 648.00M |
| September 30, 2021 | 521.00M |
| June 30, 2021 | 421.00M |
| March 31, 2021 | 401.00M |
| December 31, 2020 | 759.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 344.00M |
| June 30, 2020 | 152.00M |
| March 31, 2020 | 115.00M |
| December 31, 2019 | 117.64M |
| September 30, 2019 | 119.64M |
| June 30, 2019 | 128.30M |
| March 31, 2019 | 130.41M |
| December 31, 2018 | 150.43M |
| September 30, 2018 | 109.05M |
| June 30, 2018 | 104.48M |
| March 31, 2018 | 90.12M |
| December 31, 2017 | 117.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
115.00M
Minimum
Mar 2020
1.406B
Maximum
Dec 2023
624.56M
Average
554.00M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co Inc | 9.627B |
| Pfizer Inc | 2.815B |
| Eli Lilly and Co | 2.563B |
| Johnson & Johnson | 3.542B |
| Novavax Inc | 164.70M |